About Us

ACE NanoMed Ltd is a Research and Development (R & D) company aiming to invent and commercialize first-in-class therapeutics with highly specific targeting effects to Epstein-Barr virus (EBV)-associated malignancies, including nasopharyngeal carcinoma (NPC), gastric cancer, Burkitt’s lymphoma and Hodgkin lymphoma. We strive to implement aptamer-based and mRNA-based innovative drugs into clinical practice for patient treatments. These drugs are devised to target and induce the death of EBV-infected cancer cells, thereby sparing the normal cells in the body safe from the therapy, as well as lessening the side effects endured by the patients. Team members at ACE NanoMed consist of both active scientists with passion for entrepreneurship in the biotechnology & nanomedicine industry and experts in finance management.